Bridging the Gap: Transforming Knowledge into Action
July 8-12, 2006, Washington, DC, USA
Monday, 10 July 2006 - 12:00 PM 84-85
Management of Prostate Cancer among Patients Presenting with Prostatic Disease in a Single Urology Practice in Southern Nigeria
Philip N. Akumabor, MBBS, FRCS, FWAC, Surgery, Urology Unit, University of Benin Teaching Hospital, Benin-City, Nigeria, College of Medicine, Ugbowo Campus, Benin-City, Edo State, None, Nigeria, J.U. Aligbe, MBBS, FMCPath, Pathology, University of Benin Teaching Hospital, Benin-City, Nigeria, Benin-City, None, Nigeria, and Flora A. M. Ukoli, MBBS, DPH, MPH, Surgery, Meharry Medical College, 1005 Dr. D. B. Todd,Jr. Blvd, Nashville, TN 37208.
Objective:To determine prevalence and pattern of presentation, and to describe the quality of care of prostate cancer patients presenting in a urological out-patient in Southern Nigeria. Methods:The case records of all men with prostatic diseases seen at Zuma Medical Center, Benin-City, Nigeria, between 2001 – 2004, were reviewed. These patients were either referred from a general hospital or walk-in patients. They all received full urological appraisal that included physical examination, digital rectal examination (DRE), ultrasonograph, prostate specific antigen (PSA), and transrectal prostate biopsy. Patient management was based on diagnosis, stage of disease, and patient preference. Treatment for non-localized disease was anti-androgen or LHRH, and bilateral orchidectomy was the second treatment option. Results:Of the 222 patients seen during this period, 45(20.3%) were diagnosed with prostate cancer on the basis of histological findings. DRE accurately identified 38(17.1%) of the cases. 8(17.8%) were aged 50-60 years, 12(26.7%) 61-70 years and 25(55.6%) were 71 years or older. None of the patients presented with organ confirmed disease. 8(17.8%) received anti- androgen or L.H.R.H treatment, 32(71.1%) opted for bilateral orchidectomy, 5(11.1%) who refused orchidectomy, or who could not afford anti-androgens, were placed on ‘watchful waiting' with PSA evaluation every 6 months.